The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
PHASE2
The purpose of this study is to evaluate the safety and tolerability of lon...
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
N/A
This study measures circulating, misfolded ATTR oligomers in asymptomatic A...
Status
Completed
Location
Cleveland Clinic
Start Date
2018-02-01
Trial ID
NCT03431896
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
N/A
The purpose of this study is to collect and evaluate pregnancy outcomes, pr...
Status
Recruiting
Location
Clinical Trial Site
Start Date
2020-08-01
Trial ID
NCT05040373
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
PHASE3
The purpose of this study is to evaluate the safety and efficacy of long-te...